SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH Day	Month	Year	2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET Day	Month	Year
PRIVACY	COSTA RICA		PRIVACY		42 Years	Female	Unk		MAY	2023

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)

Other Serious Criteria: med sig
Pain in the surgical area, grade 10/10 pain in the area of breast surgery, right side [Procedural pain]
Medication is very strong [Drug intolerance]
Anal irritation [Anorectal discomfort]
Bloody stools [Haematochezia]
Constipation [Constipation]
pain in the right arm [Pain in extremity]
pain in the pectoral region [Myalgia]
numbness [Hypoaesthesia]

(Continued on Additional Information Page)

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION
- ☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY
- ☐ LIFE THREATENING

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name)
#1) Abemaciclib (Abemaciclib) Tablet
#2) LOPERAMIDE (LOPERAMIDE) Capsule
(Continued on Additional Information Page)

20. DID REACTION ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☒ NA

15. DAILY DOSE(S)	16. ROUTE(S) OF ADMINISTRATION
#1) 150 mg, bid	#1) Oral
#2) 20 mg, bid	#2) Oral

17. INDICATION(S) FOR USE
#1) BREAST CANCER (Breast cancer)
#2) Diarrhea (Diarrhoea)

21. DID REACTION REAPPEAR AFTER REINTRODUCTION? ☐ YES ☐ NO ☒ NA

18. THERAPY DATES(from/to)	19. THERAPY DURATION
#1) 17-MAY-2023 / Unknown	#1) Unknown
#2) Unknown	#2) Unknown

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)
#1) GLUTAPAK 10 (LEVOGLUTAMIDE, MALTODEXTRIN) Unknown ; Unknown
#2) VITAMIN D [VITAMIN D NOS] (VITAMIN D [VITAMIN D NOS]) Unknown ; Unknown
#3) CALCIUM (CALCIUM) Capsule ; Unknown
#4) ZOLADEX (GOSERELIN ACETATE) Implant ; OCT-2022 / Unknown
#5) ARIMIDEX (ANASTROZOLE) Tablet ; OCT-2022 / Unknown

23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

From/To Dates	Type of History / Notes	Description
Unknown	Medical Condition	Lymphedema (Lymphoedema)
	radiotherapy it caused lymphedema in her right arm	
31-OCT-2022 to Unknown	Procedure	Radical mastectomy (Radical mastectomy)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER
Eli Lilly Interamerica Inc (AR Branch)
Tronador 4890 - Piso 12
Buenos Aires, Capital Federal CP: 1430 ARGENTINA
Phone: 54 1145464000

26. REMARKS

24b. MFR CONTROL NO.
CR202305017253

24c. DATE RECEIVED BY MANUFACTURER
01-APR-2025

24d. REPORT SOURCE
☒ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL ☐ OTHER:

DATE OF THIS REPORT
07-APR-2025

25a. REPORT TYPE
☒ INITIAL ☐ FOLLOWUP:

25b. NAME AND ADDRESS OF REPORTER
NAME AND ADDRESS WITHHELD.

NAME AND ADDRESS WITHHELD.

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

infrequent pain that did not let her sleep [Sleep disorder due to a general medical condition]
Headache [Headache]
Sour stomach [Dyspepsia]
Dizziness [Dizziness]
Diarrhea (first episode) [Diarrhoea]
Vomiting [Vomiting]
Diarrhea (second episode) [Diarrhoea]
Low hematocrit drop 32 [Haematocrit decreased]
low hemoglobin drop 11 [Haemoglobin decreased]

Case Description: This solicited case reported by a consumer via a patient support program (PSP) from business partner, with additional information from the initial reporter via PSP from business partner, concerned a 42-year-old (at the time of initial report) female patient of an unknown origin.

Medical history was included in Jun-2022, she underwent eight chemotherapies, on 31-Oct-2022 a mastectomy was performed, In Jan-2023, she had 15 radiotherapies, which caused lymphedema in her right arm, it was an inflammation of the right arm, it was an effect like a burn in the lymph nodes, which meant that not enough lymph was produced, which produced more inflammation than normal in the whole arm, she finished the radiotherapy in Feb-2023. Concomitant medications included levoglutamide/ maltodextrin, vitamin D and calcium capsule for an unknown indication.

The patient received abemaciclib (Verzenio) tablets, 150 mg, twice daily, orally, for the treatment of breast cancer, beginning on 17-May-2023 or 24-May-2023 or 14-Jul-2023 (conflicting information). She also received goserelin acetate implant, injectable, and anastrazole for the treatment to prevent the cancer from returning, she also received loperamide (unknown manufacturer) capsules, 20 mg, twice a day, orally, for the treatment of diarrhea; therapy stat date, was not reported. On 24-May-2023 or 25-May-2023 (conflicting date provided), after starting abemaciclib therapy, she had diarrhea three times a day. On 25-May-2023, abemaciclib therapy was very strong, which made her stomach sour. She was not dehydrated and was stable. She received loperamide as corrective treatment for diarrhea, and bacillus clausii as corrective treatment for sour stomach. Further, it was reported that she presented with sporadic diarrheal stools. On 21-Jun-2023, she had three diarrheal stools and anal irritation. On an unknown date, she discontinued loperamide because she experienced constipation, dizziness, vomiting and headache. Therefore, on 22-Jun-2023, she started hyoscine butylbromide (buscapine), indicated by the oncologist. On 05-Oct-2023, she presented bloody stools, when she defecated a moderate amount. Her treating physician was informed. As of 06-Oct-2023, she continued with a lot of diarrhea. Since 08-Mar-2024, she has had pain in the right arm and pectoral region and numbness so X-rays and USG were taken of the places where she had pain. On 01-Apr-2024, she will have an appointment with her treating physician to discuss the results. She went to a pain clinic and was given analgesia (acetaminophen with codeine and ibuprofen). On an unknown date, the result of breast ultrasound performed showed, soft tissues of the pectoral region and right axilla are explored, observing preservation of the different soft planes, with expected scar changes, no masses, nodules or collections were observed. Muscular planes of preserved appearance without areas of tears or hematomas. She did not take abemaciclib for 22 days due to unavailability. On an unknown date, abemaciclib was resumed, she again sometimes had diarrhea (second episode), she identified that it depends on the food she ate. On an unknown date, she underwent a planned surgery to repair both breasts, but in the breast of the mastectomy that was performed due to the tumor she presented, they left her a spander, to open the field to be able to place the mammary impalement, as a result of the surgery she suffered a drop in her hematocrit in 32 and hemoglobin in 11 (unit and reference value was not provided), due to the vacation period she did not achieve medical evaluation, and at the time of the report she was stable without complications. On 10-Jan-2025, she presented with grade 10/10 pain in the area of breast surgery, right side. They had placed an expander to make the skin stretch and to be able to place a breast prosthesis. She started with an infrequent pain that did not let her sleep and did not let her do her normal work, she had consulted but they only provided her with the treatment. She would be consulting again. The event of post procedural pain was considered as serious by the reporter due to medically significant reasons. On unknown date, she underwent an unspecified surgery. Furthermore, upon follow-up, she confirmed that the surgery was on 01-Mar-2025, this operation was a breast reconstruction where she had a radial mastectomy for breast cancer. She had already recovered and went back to work on 07-Mar-2025. Information regarding further corrective treatments was not provided. Outcome of the event of diarrhe (first episode) was recovered, outcome of the events of dyspepsia, anorectal discomfort, drug intolerance, diarrhea (second episode), bloody stools, pain in the right arm, muscle pain, numbness, haematocrit decreased, and haemoglobin decreased was not resolved, whereas for remaining events it was unknown. Abemaciclib therapy status was ongoing, while for loperamide was discontinued.

The reporting consumer did not provide a relatedness assessment between the events, abemaciclib and loperamide therapies.

Update 26-Jun-2023: Additional information was received from the initial reporter on 19-Jun-2023. Added one dosage regimen, one treatment drug and one non-serious event of dyspepsia. Updated loperamide as treatment for diarrhea from concomitant and narrative with new information accordingly.

Update 29-Jun-2023: Additional information was received from the initial reporter on 23-Jun-2023. Added one dosage regime of abemaciclib drug, one concomitant medication, six non-serious events of drug intolerance, anorectal discomfort, constipation, dizziness, vomiting and headache. Updated loperamide as suspect drug from treatment drug and narrative with new information accordingly.

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Update 12-Sep-2023: Additional information was received from reporting consumer on 06-Sep-2023. Added secondary reporter. Updated the outcome from unknown to not resolved for the event of anorectal discomfort. Updated the narrative with new information.

Update 12-Oct-2023: Information received on 06-Oct-2023, and 09-Oct-2023 was processed together. Additional information was received from the initial reporter via a business partner. Added a new therapy start date for abemaciclib, and one non-serious event of bloody stools. Updated narrative with new information.

Update 04-Apr-2024: Additional information was received from the initial reporter via PSP on 31-Mar-2024 and 01-Apr-2024 was processed together. Added one medical history, one lab data, two treatment drugs and three non-serious events of pain in the right arm, muscle pain and numbness. Updated causality as reported and causality as determined as per the PSP report for all the events. Updated narrative with new information.

Update 03-Jul-2024: Additional information was received from the initial reporter via PSP on 28-Jun-2024. Added dosage regimen with new batch D669613 of abemaciclib and one non-serious event of diarrhea (second episode), four medical history and two concomitant medications of goserelin acetate and anastrazole. Updated outcome of diarrhea (first episode) was updated from not resolved to resolved, as determined causality of events headache, sour stomach and dizziness from no to yes and the listedness from unlisted to listed, narrative with new information.

Update 25-Dec-2024: Additional information was received from the initial reporter via PSP on 20-Dec-2024. Added two lab data and two non-serious events of haematocrit decreased and haemoglobin decreased. Updated narrative with new information.

Update 29-Jan-2025: Additional information was received from the initial reporter via PSP from business partner on 24-Jan-2025. This case was upgraded to serious upon addition of one serious event of post procedural pain via medically significant reason. Added one non-serious event of sleep disorder due to a general medical condition, onset date for the event of numbness, and updated narrative with new information.

Update 27-Mar-2025: Additional information was received from an initial reporting consumer via PSP on 24-Mar-2025. No other medically significant information was provided, and no other changes were made in the case, just updated minor information in narrative. Updated narrative with new information.

Update 07-Apr-2025: Additional information was received from the initial reporter in response to questionnaire via PSP on 01-Apr-2025. Added information regarding recent surgery (breast re-construction). Updated narrative with new information.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1		Haematocrit (unit and reference value was not provided)	32	
2		Haemoglobin (unit and reference value was not provided)	11	
3		Ultrasound breast Soft tissues of the pectoral region and right axilla are explored, observing preservation of the different soft planes, with expected scar changes, no masses, nodules or collections are observed. Muscular planes of preserved appearance without areas of tears or hematomas.		

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) Abemaciclib (Abemaciclib) Tablet {Lot # B590310; Exp.Dt. 31-JUL-2025}; Regimen #2	150 mg, bid; Oral	BREAST CANCER (Breast cancer)	Unknown; Unknown
#1) Abemaciclib (Abemaciclib) Tablet {Lot # D669613; Exp.Dt. APR-2026}; Regimen #3	150 mg, bid; Oral	BREAST CANCER (Breast cancer)	Ongoing; Unknown

Mfr. Control Number: CR202305017253

ADDITIONAL INFORMATION

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
JUN-2022 to Unknown	Procedure total of 8 chemotherapies approximately in the course of 2 months	Chemotherapy (Chemotherapy);
JAN-2023 to FEB-2023	Procedure total of 15 were carried out	Radiotherapy (Radiotherapy);